Viridian Therapeutics, Inc.\DE 8-K

What Happened
Viridian Therapeutics, Inc. (NASDAQ: VRDN) filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held June 2, 2026. Shareholders of record as of April 7, 2026 (103,071,889 shares outstanding) voted to elect two Class II directors and approved other proposals, including ratification of KPMG LLP as the company’s independent registered public accounting firm and non-binding advisory votes on executive compensation and the frequency of those votes.

Key Details

• Record date and shares outstanding: April 7, 2026; 103,071,889 shares issued and outstanding.
• Director elections (Class II, terms to 2029):
  • Tomas Kiselak — For: 72,363,500; Withheld: 14,475,646; Broker non-votes: 6,733,104.
  • Jennifer K. Moses — For: 86,378,842; Withheld: 460,304; Broker non-votes: 6,733,104.
• Auditor ratification: KPMG LLP approved — For: 92,866,008; Against: 512,582; Abstentions: 193,660.
• Advisory votes on executive pay:
  • Say-on-pay (non-binding) approved — For: 83,512,086; Against: 3,113,724; Abstentions: 213,336; Broker non-votes: 6,733,104.
  • Frequency vote result — 1 year preferred: 86,084,347; 2 years: 29,762; 3 years: 517,682; Abstain: 207,355. Board will hold advisory pay votes annually.

Why It Matters
The meeting outcomes confirm board continuity with the two director nominees elected through 2029 and formalize the company’s auditor (KPMG) for fiscal 2026 — both items relevant to governance and financial oversight. The non-binding approval of executive compensation and the decisive vote for annual advisory votes signal shareholder support (and the company’s commitment) to regular, yearly say-on-pay disclosures. For investors, these governance votes affect oversight, transparency, and potential accountability around management and financial reporting.